$2.03
3.05% today
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US23666P1012
Symbol
DARE

Dare Bioscience, Inc. Stock price

$1.97
-0.55 21.67% 1M
-1.17 37.26% 6M
-1.15 36.86% YTD
-1.53 43.71% 1Y
-12.19 86.09% 3Y
-12.31 86.20% 5Y
-455.23 99.57% 10Y
-820.03 99.76% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.05 2.60%
ISIN
US23666P1012
Symbol
DARE
Industry

Key metrics

Basic
Market capitalization
$17.4m
Enterprise Value
$14.3m
Net debt
positive
Cash
$10.3m
Shares outstanding
8.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
193.7 | 2.4
EV/Sales
159.3 | 2.0
EV/FCF
2.4
P/B
negative
Financial Health
Equity Ratio
-27.2%
Return on Equity
67.4%
ROCE
63.5%
ROIC
-
Debt/Equity
-0.8
Financials (TTM | estimate)
Revenue
$90.0k | $7.3m
EBITDA
$-1.4m | -
EBIT
$-1.6m | $-22.9m
Net Income
$-1.7m | $-17.7m
Free Cash Flow
$6.0m
Growth (TTM | estimate)
Revenue
-96.8% | 73,170.0%
EBITDA
95.0% | -
EBIT
94.3% | 2.3%
Net Income
94.2% | -337.5%
Free Cash Flow
119.9%
Margin (TTM | estimate)
Gross
108.5%
EBITDA
-1,608.4% | -
EBIT
-1,820.1%
Net
-1,871.1% | -241.8%
Free Cash Flow
6,711.6%
More
EPS
$-0.2
FCF per Share
$0.7
Short interest
12.7%
Employees
22
Rev per Employee
$0.0
Show more

Is Dare Bioscience, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Dare Bioscience, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Dare Bioscience, Inc. forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Dare Bioscience, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Dare Bioscience, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.09 0.09
97% 97%
100%
- Direct Costs -0.01 -0.01
200% 200%
-11%
0.10 0.10
-
111%
- Selling and Administrative Expenses 8.87 8.87
23% 23%
9,856%
- Research and Development Expense 13 13
34% 34%
14,633%
-1.44 -1.44
95% 95%
-1,600%
- Depreciation and Amortization 0.19 0.19
375% 375%
211%
EBIT (Operating Income) EBIT -1.63 -1.63
94% 94%
-1,812%
Net Profit -1.68 -1.68
94% 94%
-1,867%

In millions USD.

Don't miss a Thing! We will send you all news about Dare Bioscience, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dare Bioscience, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide ...
Neutral
GlobeNewsWire
14 days ago
A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most
Neutral
GlobeNewsWire
22 days ago
A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most
More Dare Bioscience, Inc. News

Company Profile

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Head office United States
CEO Sabrina Johnson
Employees 22
Founded 2015
Website www.darebioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today